01/13/21 5:30 PMNYSE : PENROSEN, GLOBAL INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Penumbra, Inc. - PENRosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Penumbra, Inc. (NYSE: PEN) resulting from allegations that Penumbra may have issued materially misleading business informationRHEA-AInegative
01/11/21 8:00 AMNYSE : PENPenumbra Announces Preliminary Unaudited Revenue for the Fourth Quarter and Full Year 2020Penumbra, Inc. (the "Company") ( NYSE: PEN), a global healthcare company focused on innovative therapies, today announced certain unaudited preliminary revenue results for the fourth quarter and full year 2020 ahead of its participation at the 39 thRHEA-AInegative
12/18/20 7:48 PMNYSE : PENKessler Topaz Meltzer & Check, LLP is Investigating Claims on Behalf of Penumbra, Inc. (NYSE: PEN) Investors The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of law under the federal securities laws on behalf of shareholders of Penumbra, Inc. ("Penumbra") (NYSE: PEN).Headquartered in Alameda, California, Penumbra is a global healthcare company focused onRHEA-AIvery negative
12/17/20 2:25 PMNYSE : PENKessler Topaz Meltzer & Check, LLP Is Investigating Claims On Behalf Of Penumbra, Inc. (NYSE: PEN) InvestorsThe law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of law under the federal securities laws on behalf of shareholders of Penumbra, Inc. ("Penumbra") (NYSE: PEN).Headquartered in Alameda, California,RHEA-AIvery negative
12/16/20 9:32 PMNYSE : PENPEN INVESTIGATION ALERT: Bernstein Liebhard is Investigating Penumbra, Inc. For Violations of the Securities LawsBernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN) resulting from allegations that Penumbra might haveRHEA-AInegative
12/16/20 11:30 AMNYSE : PENThe Law Offices of Frank R. Cruz Announces Investigation of Penumbra, Inc. (PEN) on Behalf of InvestorsThe Law Offices of Frank R. Cruz announces an investigation of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN) on behalf of investors concerning the Company's possible violations of federal securities laws.If you are a shareholder who suffered a loss, click here to participate.OnRHEA-AIvery negative
12/15/20 8:00 PMNYSE : PENINVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Penumbra, Inc. (PEN) on Behalf of InvestorsLaw Offices of Howard G. Smith continues its investigation on behalf of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN) investors concerning the Company and its officers' possible violations of federal securities laws.On November 10, 2020, Quintessential Capital Management issued aRHEA-AIvery negative
12/15/20 4:05 PMNYSE : PENPenumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary RecallPenumbra, Inc. (NYSE: PEN) today announced that it is voluntarily recalling all configurations of the Penumbra JET (R) 7 Reperfusion Catheter with Xtra Flex technology (JET 7 Xtra Flex). Penumbra is recalling JET 7 Xtra Flex because the catheter mayRHEA-AIvery negative
12/10/20 9:50 PMNYSE : PENROSEN, TRUSTED AND LEADING INVESTOR COUNSEL, Commences Investigation of Securities Claims Against Penumbra, Inc. Seeking Recovery of Investor Losses; Encourages Investors with Losses Over $100K to Seek Counsel - PENRosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Penumbra, Inc. (NYSE: PEN) resulting from allegations that Penumbra may have issued materially misleading businessRHEA-AIneutral
12/08/20 2:42 PMNYSE : PENPenumbra Responds to False Allegations from Short Sellers Seeking to Manipulate Company Stock and Remove Life-saving Medical Devices from the MarketPenumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today responded to recent attacks by short sellers containing inaccurate and misleading information regarding scientific research published by Penumbra's co-founderRHEA-AIneutral
